Recipe for Chaos<br />By Rev Shark<br />RealMoney.com Contributor<br />7/22/2009 8:49 AM EDT <br /><br /><br />"It is best to love wisely, no doubt, but to love foolishly is better than not to be able to love at all." <br /><br />-- William M. Thackeray. <br />Not surprisingly, Apple (AAPL) posted a very strong quarter last night, and it was even good enough to send the stock up another $7, although it had already made a very big move prior to the earnings report. <br /><br />Apple is a stock many in the market love to love because not only does the company have such a loyal following for its products but it also does such a great job of managing its earnings. Every quarter, Apple plays the same game. Management reduces guidance for the next quarter, and that sets the stage for dramatically exceeding estimates when the company reports. It isn't any secret. Everyone knows what the company is doing, but, nonetheless, it keeps a continuously positive buzz. <br /><br />This morning analysts are raising price targets for Apple to as much as $225 after the company handily beat estimates. <br /><br />With the strong Apple report now in the books, the question of the day is whether the Nasdaq can move higher for the eleventh straight day. When a market has that sort of streak, there isn't much you can do but appreciate the momentum and fight the inclination to be overly aggressive with a contrarian trade. <br /><br />Reports are hitting now from Morgan Stanley (MS) and Wells Fargo (WFC) and are looking troublesome. Both are trading down fairly sharply on the news. Banks were showing some relative weakness the last few days, but market players were focused on the promise of Apple and weren't paying much attention. <br /><br />This market continues to produce a major dilemma now. I've been saying that for several days, but the situation has not changed. We have gone straight up with barely a pause and have produced a slew of overbought and overextended charts, but momentum has showed few signs of slowing and the underlying support has been extremely strong. Finding new buys is very difficult, but shorting into the strength has not been a profitable move. <br /><br />Maybe now with Apple out of the way and some poor action in banks, we will cool off a little, but so many folks were caught by surprised when the market took off last week following Intel's (INTC) report that we are likely to have a good supply of dip buyers out there. They should keep the downside contained even if we do finally start to consolidate the recent move. <br /><br />It is impossible not to be at least a little more cautious when a market has moved as much and as quickly as this one has over the past week. That doesn't mean you have to be wildly bearish, but it just isn't prudent to keep chasing stocks that have made parabolic moves. <br /><br />My stance right now is neutral. I'd be happy to buy things that are set up, but the vast majority of charts I see need some rest. On the other hand, there is enough underlying support and buying interest that we can't expect the market to simply fall apart and go straight down. <br /><br />We have battle lines drawn today, with the love affair over Apple and technology on one side and some concerns over the banking sector on the other. Throw in an extended market and plenty of performance anxiety, and we have the recipe for some chaotic action. <br />--------------------------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: MEG +27.7%, OFG +19.8%, ATHR +10.3%, CHIC +9.5% (also upgraded to Overweight at JPMorgan), SBUX +9.1% (also upgraded to Hold from Sell at Deutsche Bank and upgraded to Buy at Argus), AAI +8.7%, PTV +6.1%, FULT +5.9%, LLTC +4.6%, ILMN +4.6%, WINN +4.4%, NITE +4.0%, CKSW +3.9% (light volume), VFC +3.5%, AAPL +3.4%, CHRW +3.0%, SXL +2.9% (light volume), STX +2.8% (also upgraded to Hold at Collins Stewart), WIT +2.4% (light volume), BA +2.3%, LLY +1.3%... Other news: ONXX +26.9% (Nexavar in combination with chemotherapy shown to extend progression-free survival in patients with advanced breast cancer), SPAR +11.9% (still checking), BDSI +8.7% (receives $27 mln milestone payment from Meda AB), SCMP +8.5% (Sucampo Pharma and Takeda report top-line results of two Phase 3 trials of lubiprostone in opioid-induced bowel dysfunction), WYNN +4.7% (Cramer makes positive comments on MadMoney), HGSI +4.0% (announces new order for Raxibacumab from U.S. government), HEB +3.6% (left the polls open with regard to voting on proposal 3, an amendment of its certificate of incorporation to increase the number of authorized shares), NVAX +1.9% (Announces Selection of a Respiratory Syncytial Announces Selection of a Respiratory Syncytial), PDA +1.3% (still checking)... Analyst comments: HNT +3.1% (upgraded to Buy from Neutral at Goldman- Reuters), MHS +1.8% (initiated with Buy at Lazard), KFT +1.5% (upgraded to Buy at Citigroup), SLT +1.0% (ticking higher, hearing upgraded at tier 1 firm). <br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: PPDI -16.2% (also downgraded to Neutral from Outperform at RW Baird), AMD -13.5%, KEY -8.7%, AAN -8.6% (also downgraded to Neutral at Cowen and downgraded to Market Perform at Raymond James), SLM -7.5%, SUPX -7.1%, STI -6.8%, USG -5.9%, AMLN -5.8%, MS -5.6%, WFC -5.3%, STJ -4.0%, YHOO -3.9%, BK -3.8%, GILD -3.2%, USB -2.5%, SU -2.2%... Select financial names showing weakness: AXA -3.4%, BCS -3.2%, PRU -3.0%, LYG -2.5%, UBS -2.2%, BAC -2.1%, COF -1.9%, HBC -1.4%, DB -1.3%, JPM -1.3%... Select oil/gas related names ticking lower: BTU -3.1% (downgraded to Hold at Citigroup), E -1.8%, COP -1.4%, PBR -1.4%, CVX -1.1%, BP -1.1%, OXY -1.0%, TOT -1.0%... Select metals/mining stocks showing weakness: BBL -2.1%, BHP -1.8% (BHP Billiton misses iron ore guidance; coal, oil strong - DJ), AAUK -1.3%, MT -1.0%... Other news: CIT -35.0% (announced that Moody's Investors Service has placed its CIT Equipment Collateral 2009-VT1 Receivable-Backed Notes under review for possible downgrade), EDR -10.9% (announces a 21 mln share common stock offering), SAY -5.0% (still checking), BPSG -4.7% (announced the commencement of a 20 mln share common stock offering, 12 mln shares being offered by the co and 8 mln share being offered by selling shareholders), CVBF -4.2% (priced a 19.7 mln common stock offering at $5.85/share), GE -1.9% (GE Capital receives approval for TLGP exit plan), NOK -1.9% (still checking)... Analyst comments: SPWRA -2.9% (downgraded to Hold at Ardour Capital), FCX -1.7% (downgraded to Hold at Citigroup).